Synthetic Tissue Substitute

CorNeat EverPatch for Glaucoma

Waitlist Available
Research Sponsored by CorNeat Vision Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Concealment of glaucoma tube shunt or suture tags is indicated
Patients with viable and intact conjunctiva
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up6 & 12 months post-op.
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test how safe and effective a new device is at hiding artificial ocular implants.

Eligible Conditions
  • Glaucoma
  • Tissue Necrosis

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have healthy and intact tissue on the surface of your eye called conjunctiva.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 & 12 months post-op.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 & 12 months post-op. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety Assessment
Secondary outcome measures
Performance Assessment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic ImplantsExperimental Treatment1 Intervention

Find a site

Who is running the clinical trial?

CorNeat Vision Ltd.Lead Sponsor
3 Previous Clinical Trials
78 Total Patients Enrolled
1 Trials studying Glaucoma
28 Patients Enrolled for Glaucoma

Media Library

CorNeat EverPatch (Synthetic Tissue Substitute) Clinical Trial Eligibility Overview. Trial Name: NCT05469867 — N/A
Glaucoma Research Study Groups: Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
Glaucoma Clinical Trial 2023: CorNeat EverPatch Highlights & Side Effects. Trial Name: NCT05469867 — N/A
CorNeat EverPatch (Synthetic Tissue Substitute) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05469867 — N/A
Glaucoma Patient Testimony for trial: Trial Name: NCT05469867 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people able to currently enroll in this research?

"According to the information provided by, this trial is not in a recruitment phase at present. The post was first made on August 1st 2022 and its most recent revision happened on July 19th 2022. Albeit inactive, there are 206 other trials actively enrolling patients right now."

Answered by AI

Is the protocol for this experiment including individuals who are beyond middle-age?

"This clinical trial stipulates that patients must be aged between 18 and 80 years old. In addition, there are 23 studies for minors under the age of 18 and 191 opportunities available to those who exceed 65 years of seniority."

Answered by AI

What type of individual would be the best candidate for this experiment?

"To be eligible for this study, subjects must have a glaucoma diagnosis and fall between the ages of 18 to 80. Sixty participants are needed in total."

Answered by AI

Who else is applying?

What site did they apply to?
EyeCare Miramichi Eye NB
University Health Network
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

I want to recover my sight. I have been diagnosed with glaucoma for the past 4years and I would like to make treatment to improve my sight.
~13 spots leftby Mar 2024